3G6 Stock Chart & Stats
€17.50
€0.40(2.20%)
At close: 4:00 PM EST
€17.50
€0.40(2.20%)
Day’s Range― - ―
52-Week Range€11.90 - €20.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€866.97M
Enterprise Value€172.97B
Total Cash (Recent Filing)€17.16B
Total Debt (Recent Filing)€5.07B
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 13, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-102.58
Shares Outstanding65,851,105
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)€226.39M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsA gross margin near 75% indicates the company retains substantial value from its revenue before operating costs. If maintained, this provides economic room to fund research, commercialization, and other strategic priorities while supporting recovery in operating profitability.
Manageable LeverageLow debt relative to equity reduces balance-sheet pressure and leaves more flexibility to manage operations, invest in growth, or absorb earnings volatility. This provides a stronger financial foundation than a highly leveraged structure during periods of weak profitability.
Revenue GrowthPositive revenue growth shows that the business has continued expanding its top line even as momentum weakened. Maintaining revenue growth can preserve operating scale and gives the company a base from which stronger margins and earnings conversion could eventually develop.
Bears Say
Negative Cash GenerationNegative operating and free cash flow means reported activity is not currently converting into sufficient internal funding. Continued cash burn can increase reliance on external funding and constrain investment capacity if profitability does not recover over the coming quarters.
Volatile ProfitabilityThe swing from strong profit to sizable losses demonstrates that earnings conversion is currently unstable despite high gross margins. Persistent negative operating and net margins could limit reinvestment, weaken returns on equity, and make financial performance difficult to forecast.
Deteriorating Earnings MomentumSharp deterioration in EPS growth signals that revenue is not translating into shareholder earnings and that operating costs or other factors are absorbing gross profit. Unless this trend reverses, earnings weakness may persist even if the top line remains positive.
GNI Group News
3G6 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €11.90 and its highest was €20.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is €866.97M.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 12 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Aug 14, 2026. The company reported €0.014 earnings per share for the quarter, beating the consensus estimate of -€0.349 by €0.364.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Overvalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is 0.15.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,851,105 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of €0.014 in its last earnings report, beating expectations of -€0.349. Following the earnings report the stock price went up 1.961%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in DE:3G6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.